Use of glargine and Lente insulins in cats with diabetes mellitus

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 234-238

  Weaver, Kelli E ^a   Rozanski, Elizabeth A ^a   Mahony, Orla M ^a   Chan, Daniel L ^a   Freeman, Lisa M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Carbohydrate; Diet; Fructosamine; Lantus; Protein

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; LONG ACTING INSULIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; DRUG ADMINISTRATION; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CAT DISEASES; CATS; DIABETES MELLITUS; DIET; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE;

FELIDAE;

EID: 33645556289     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[234:UOGALI]2.0.CO;2     Document Type: Article

References (17)

1. Panciera DL, Thomas CB, Eicker S, et al. Epizootiologic patterns of diabetes mellitus in cats: 333 cases (1980-1986). J Am Vet Med Assoc 1990;197:1504-1508.
2. Rand JS, Fleeman LM, Farrow HA, et al. Canine and feline diabetes mellitus: Nature or nurture? J Nutr 2004;134:2072S-2080S.
3. Feldman EC, Nelson RW. Diabetes mellitus. In: Feldman EC. Nelson RW. Canine and Feline Endocrinology and Reproduction. Philadelphia, PA: WB Saunders; 1996:339-391.
4. Nelson RW, Lynn RC, Wagner-Mann CC, et al. Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats. J Am Vet Med Assoc 2001;218(1):38-42.
5. Bertoy EH, Nelson RW, Feldman EC. Effect of lente insulin for treatment of diabetes mellitus in 12 cats. J Am Vet Med Assoc 1995;206(11):1729-1731.
6. Goossens MM, Nelson RW, Feldman EC, et al. Response to insulin treatment and survival in 104 cats with diabetes mellitus (1985-1995). J Vet Intern Med 1998;12:1-6.
7. Heinemann L, Linkeschova R, Rare K, et al. Time action profile of the long acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin, and placebo. Diabetes Care 2000;23:644-649.
8. McKeage K, Goa KL. Spotlight in insulin glargine in type I and 2 diabetes mellitus. Treat Endocrinol 2002;1:55-58.
9. Frank G, Anderson W, Pazak H, et al. Use of a high-protein diet in the management of feline diabetes mellitus. Vet Ther 2001;2:238-246.
10. Hess RS, Ward CR. Effect of insulin dosage on glycemic response in dogs with diabetes mellitus: 221 cases (1993-1998). J Am Vet Med Assoc 2000;216(2):217-221.
11. Broussard JD, Peterson ME. Comparison of two Ultralente insulin preparations with protamine zinc insulin in clinically normal cats. Am J Vet Res 1994;55(1):127-131.
12. Nelson RW, Feldman EC, DeVries SE. Use of Ultralente insulin in cats with diabetes mellitus. J Am Vet Med Assoc 1992;200(12):1828-1829.
13. Lepore M, Kurzhals R, Pampanelli S, et al. Pharmacokinetics and dynamics of s.c. injection of the long acting insulin glargine (HOE901) in TIDM. Diabetes 1999;48(1):A97.
14. Pieber TR, Eugene-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23(2):157-162.
15. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23(8):1137-1142.
16. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23(5):639-643.
17. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes. Diabetes Care 2001;24(4):631-635.